http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
한국 원자력 발전소의 제어실에 대한 인간공학 분야 심사
최성남,변승남 慶熙大學校 材料科學技術硏究所 1999 材料科學技術硏究論集 Vol.12 No.-
Presently Korea has fourteen operating Nuclear Power Plants(NPPs) and six units under construction since 1989. Human Factors Engineering(HFE) activities have been classified into two categories. For plants built prior to 1989, all design modifications and improvements have been performed on the basis of the U.S. NRC requirements and guidelines according to the Post-TMI action plan. However, new NPPs built and put into commercial operation after 1989, have incorporated chapter 18 of the HFE in the Safety Analysis Report in order to assure the safety from the early stage of designing process. This study presents the regulation methodology and its results, HFE issues, design improvements, and practices that we have experienced in the past 10 years. This study also introduces HFE regulation strategies in Korea for the future NPPs.
양성갑상선종물 환자에서 갑사선 호르몬 억제요법과 갑상선 호르몬과 항갑상선제 병합요법의 치료효과 비교
최성남,공병호,배현철,오연상,신순현 중앙대학교 의과대학 의과학연구소 1998 中央醫大誌 Vol.23 No.1
Traditionally, patients with nontoxic benign thyroid nodule has been treated with levothyroxine. The successful treatment of T4 suppressive therapy, however, has been observed in 50 % of patients with thyroid nodules oven though the treatment were continued more than 1 year. The side effects such as osteoporosis, left ventricular hypertrophy has been observed. Therefore, we performed this study to evaluate the efficacy of the new treatment modality (levothyroxine and methimazole combination) in the treatment of thyroid nodule. Study population was 67 patients having nontoxic benign thyroid nodule. Serum TSH, fT4, T3 and thyroid nodular volume were measured at pretreatment and post-treatment periods. The benign thyroid lesion was confirmed by FNAC (fine needle aspiration cytology). The factors can be influenced on therapeutic response were also studied. The patients were divided into two groups. One group had been treated with levothyroxine only and the other with levothyroxine and anthithyroid drug combination. 47 patients had been treated with levothyroxine only. The other 20 patients had received combination therapy with levothyroxine and methimazole. The mean age and sex ratio, pretreatment nodular volume, TSH, fT4 and total T3 level measured at pretreatment and post-treatment had no stastistical difference between two groups. The combination therapy group had been treated for 8.4 ± 2.6 months and T4 suppressive therapy group for 11.1 ± 4.8 months (P=0.03). Pretreatment TSH concentration was 0.99 ± 0.60 μIU/ml in T4 suppressive therapy group, 1.43 ± 1.21 μIU/ml in combination therapy group. (P=0.023) But the value of serum TSH in both groups was in normal range. The responder group was 17 patients and the response rate was 85 % in combination therapy group and 25 and 53 % in T4 suppressive group. In the combination therapy group, the volume reduction was more greater. (71.5% in combination group, 18.1 % in T4 group) In conclusion, combination therapy can reduce treatment duration, enhance therapeutic response rate for the treatment of benign thyroid nodule. The exact mechanism of methimazole on thyroid nodule wan not not clearly known. Perhapse, the influence of methimazole on the transcription factor may be involved Further study in this regard is needed in the future.